Polyarticular Juvenile Idiopathic Arthritis (DBCOND0025601)

Identifiers

Synonyms

Polyarticular Course Juvenile Idiopathic Arthritis / Polyarticular-course Juvenile Idiopathic Arthritis (JIA) / Polyarticular juvenile idiopathic arthritis / Polyarticular juvenile idiopathic arthritis (disorder) / Juvenile arthritis, unspecified / Arthritis, Juvenile / Juvenile arthritis / Juvenile idiopathic arthritis / Juvenile idiopathic arthritis (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Abatacept	A disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.	T-lymphocyte activation antigen CD80target T-lymphocyte activation antigen CD86target Cytotoxic T-lymphocyte protein 4target
Adalimumab	A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.	Tumor necrosis factortarget
Etanercept	A protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.	Tumor necrosis factortarget Lymphotoxin-alphatarget Low affinity immunoglobulin gamma Fc region receptor III-Btarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget High affinity immunoglobulin gamma Fc receptor Itarget Low affinity immunoglobulin gamma Fc region receptor II-atarget Low affinity immunoglobulin gamma Fc region receptor II-btarget Low affinity immunoglobulin gamma Fc region receptor II-ctarget Complement component 1q (C1q)target
Methotrexate	An antineoplastic agent used the treatment of a wide variety of cancers as well as severe psoriasis, severe rheumatoid arthritis, and juvenile rheumatoid arthritis.	Dihydrofolate reductasetarget Aldehyde oxidaseenzyme Methylenetetrahydrofolate reductase (NADPH)enzyme Albumincarrier ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 4transporter Multidrug resistance-associated protein 1transporter Solute carrier family 22 member 6transporter ATP-binding cassette sub-family C member 10transporter Organic anion transporter 3transporter ATP-binding cassette sub-family C member 2transporter ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 1A2transporter Monocarboxylate transporter 1transporter ATP-binding cassette sub-family C member 11transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 11transporter Solute carrier organic anion transporter family member 1C1transporter Solute carrier organic anion transporter family member 3A1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 7transporter Solute carrier organic anion transporter family member 1B1transporter 6-phosphogluconate dehydrogenase, decarboxylatingenzyme Proton-coupled folate transportertransporter Folylpolyglutamate synthase, mitochondrialenzyme Gamma-glutamyl hydrolaseenzyme Dihydrofolate reductaseenzyme Thymidylate synthaseenzyme Bifunctional purine biosynthesis protein ATICenzyme Solute carrier organic anion transporter family member 4C1transporter Reduced folate transportertransporter Folate receptor alphatransporter Cytochrome P450 3A4enzyme Thymidylate synthasetarget Bifunctional purine biosynthesis protein ATICtarget Folate receptor betatransporter Solute carrier family 15 member 1transporter Proton-coupled amino acid transporter 1transporter Carboxypeptidase G2enzyme Proton-coupled folate transportertarget Reduced folate transportertarget
Tocilizumab	An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).	Interleukin-6 receptor subunit alphatarget Cytochrome P450 3A4enzyme
Tofacitinib	A Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis.	Non-receptor tyrosine-protein kinase TYK2target Cytochrome P450 3A4enzyme Cytochrome P450 2C19enzyme Tyrosine-protein kinase JAK2target Tyrosine-protein kinase JAK1target Tyrosine-protein kinase JAK3target Albumincarrier

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05754710	Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis	Tofacitinib	Not Available	Not Available	active_not_recruiting
NCT05411211	An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)	No drug interventions	Not Available	Not Available	completed
NCT02141984	Surveillance of Humira in Korean JIA Patients	No drug interventions	Not Available	Not Available	completed
NCT04018599	Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS	Adalimumab	basic_science	1	completed
NCT00144625	Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)	Tocilizumab	treatment	3	completed
NCT01261624	Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis	Givinostat	treatment	2	terminated
NCT01550003	Pediatric Arthritis Study of Certolizumab Pegol	Certolizumab pegol	treatment	3	completed